MedTrace Logo

Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction

NCT03129594 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 709

Last updated 2017-10-04

No results posted yet for this study

Summary

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Conditions

  • Coronary Angiography
  • Glucagon-like Peptide-1

Interventions

DIAGNOSTIC_TEST

plasma glucagon-like peptide-1 levels

The plasma GLP-1 levels was determined by enzymatic assays.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-02-28
Completion
2015-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129594 on ClinicalTrials.gov